Share Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis

GlobeNewsWire · CLDX · November 19, 2026

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: GlobeNewsWire ↗